Global burger giant McDonald’s is selling a lot more more kid-sized cheeseburgers to adults than it did a few years ago. It's an example of the unusual food industry and consumer market distortions ...

Millions of Americans taking blockbuster weight-loss drugs like Ozempic and Mounjaro are eating less food overall. But what ...

With Wegovy HD, Novo Nordisk (DK:NOVO.B) (NVO) can better compete against Eli Lilly (LLY), which markets Zepbound, a GLP-1 injection also known as tirzepatide that produced 22.5% weight loss in a ...

Novo Nordisk’s 7.2 mg dose of Wegovy will compete against Lilly’s GLP-1 injection.

Novo Nordisk's India patent expiry today unlocks affordable semaglutide, set to transform diabetes and weight management.

California is denying popular and effective weight loss drugs to poor people — likely to spite President Donald Trump, who has tried to make them cheaper.

Comedian Gabriel Iglesias shared his experience with Ozempic, revealing that he quit the medication after five months and quickly regained 20 lbs.

In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster ...

However, experts said there’s limited scientific evidence that many peptides are safe and effective. Peptides are having a moment, promoted by everyone from wellness influencers and celebrities to ...

People take GLP-1 drugs like Wegovy, Ozempic, Mounjaro, and Zepbound for a variety of reasons, from controlling diabetes and sleep apnea to managing weight and enjoying benefits to the heart, liver, ...

A major study links Wegovy to a rare form of sudden vision loss, and finds men may face three times the risk of women.